39. 中毒性表皮壊死症 [臨床試験数:11,薬物数:17(DrugBank:9),標的遺伝子数:11,標的パスウェイ数:97]
Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02987257 | December 2020 | 2 September 2019 | Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis | Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults | Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses | Drug: cyclosporin A;Drug: Etanercept 50 MG Solution for Injection;Drug: Placebos | Vanderbilt University Medical Center | University of Ottawa;University of Toronto;Loyola University;University of South Florida;University of Texas | Not recruiting | 18 Years | N/A | All | 267 | Phase 3 | United States |
2 | NCT03585946 | September 1, 2018 | 16 July 2018 | Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug Reaction | Drug: Site specific standard of care comparison | Massachusetts General Hospital | Not recruiting | 18 Years | N/A | All | 750 | N/A | ||
3 | JPRN-jRCTs061180044 | 01/06/2017 | 22 July 2019 | Multicenter Open-trial of Steroid pulse therapy for SJS/TEN | Multicenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study | Stevens-Johnson syndrome and Toxic epidermal necrolysis | 1. infusion of methylprednisolone at 500~1000 mg/d (0.9% N/S in 3 hour) for 3 consecutive days. 2. Oral predonisolone (0.5 mg/kg/d) was initiated on the day following the last dose of methylprednisolone, and prednisolone was subsequently tapered within 2 weeks. If the ocular involvement score is more than 2, dose of oral predonisolone (1 mg/kg/d) is recommended. | Eishin Morita | Recruiting | 20 age old | 90 age old | Both | 20 | Phase 2 | Taiwan;Germany | |
4 | NCT02319616 | November 2016 | 26 August 2019 | Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis | A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) | Toxic Epidermal Necrolysis | Drug: Clobetasol 0.05% ointment;Drug: Placebo | University of California, Davis | Not recruiting | 7 Years | 85 Years | All | 0 | Phase 1/Phase 2 | United States | |
5 | NCT02795143 | November 2016 | 9 January 2017 | Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study | Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study | Toxic Epidermal Necrolysis | Drug: Isotretinoin;Other: Placebo | Massachusetts General Hospital | Recruiting | 18 Years | 69 Years | Both | 40 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT02739295 | July 2016 | 6 May 2019 | G-CSF in the Treatment of Toxic Epidermal Necrolysis | Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis | Stevens - Johnson Syndrome | Drug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9% | University Hospital of Liege | Recruiting | 18 Years | N/A | All | 10 | Phase 4 | Belgium | |
7 | NCT02126020 | November 2014 | 16 December 2017 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid | Drug: topical infliximab | James Chodosh, MD, MPH | Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM) | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 1/Phase 2 | United States;Canada |
8 | NCT01696500 | October 2012 | 19 February 2015 | Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Drug: Intravenous immunoglobulin | Nihon Pharmaceutical Co., Ltd | Not recruiting | 20 Years | N/A | Both | 10 | Phase 3 | Japan | |
9 | NCT01256489 | December 2010 | 17 November 2015 | Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) | Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis | Stevens-Johnson Syndrome;Corneal Blindness | Drug: Infliximab | Massachusetts Eye and Ear Infirmary | Not recruiting | 18 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States | |
10 | NCT02037347 | October 2010 | 19 October 2017 | Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis | Palifermin Treatment of Toxic Epidermal Necrolysis | Toxic Epidermal Necrolysis;Stevens-Johnson Syndrome | Drug: Palifermin | Brett King | Swedish Orphan Biovitrum | Not recruiting | 18 Years | N/A | All | 1 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT00372723 | July 2006 | 19 February 2015 | Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) | Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis | Toxic Epidermal Necrolysis | Drug: Remicaide (infliximab) | Loyola University | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2 | United States |